Technology | June 08, 2008

New Ultrasound Agent for Heart Disease Submitted to FDA

Acusphere has submitted a New Drug Application (NDA) to the FDA for approval to market Imagify (Perflubutane Polymer Microspheres for Injectable Suspension), an ultrasound imaging agent for the detection of coronary artery disease, which could prove as accurate as nuclear stress testing.
The NDA includes data from studies of Imagify in more than 1,000 patients worldwide, including two pivotal international multicenter Phase III clinical trials, RAMP-1 and RAMP-2 (Real-Time Assessment of Myocardial Perfusion).
Imagify is the first ultrasound imaging agent designed to assess blood flow in the heart (myocardial perfusion), a sensitive marker of coronary artery disease. The company believes it is also the first ultrasound imaging agent to demonstrate in large clinical trials clinically equivalent accuracy to nuclear stress testing, the current standard for assessing myocardial perfusion. Currently, perfusion information is not available using cardiac ultrasound, but must be obtained using a nuclear stress test, which involves injecting the patient with a radioactive imaging agent.

June 2008

Related Content

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | September 12, 2018
In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore co
Scientists Develop New MRI Tool for Cancer Diagnosis and Therapy

Researchers in the laboratory ‘Biomedical Nanomaterials’ of NUST MISIS. Image courtesy of PR Newsfoto/NUST MISIS.

News | Oncology Diagnostics | August 24, 2018
A European research group has developed a system that allows doctors to both improve the accuracy of diagnosing...
Iron Outperforms Gadolinium as MRI Contrast Agent

Scientists at Rice's Laboratory for Nanophotonics added iron chelates (blue) and fluorescent dye (red) to multi-layered gold nanomatryoshkas to create particles that can be used for disease therapy and diagnostics. The "theranostic" nanoparticles have a core of gold (left) that is covered by silica containing the diagnostic iron and dye, which is covered by an outer shell of gold. The particles are about 20 times smaller than a red blood cell, and by varying the thickness of the layers, LANP scientists can tune the nanomatryoshkas to convert light into cancer-killing heat. (Image courtesy of Luke Henderson/Rice University)

News | Contrast Media | August 22, 2018
Rice University nanoscientists have demonstrated a method for loading iron inside nanoparticles to create magnetic...
Guerbet Partners With Imalogix on Dose Optimization With Artificial Intelligence
News | Radiation Dose Management | August 14, 2018
August 14, 2018 — Guerbet LLC USA announced a commercial partnership with Imalogix, a provider of...
Videos | Contrast Media | August 03, 2018
Lawrence Tanenbaum, M.D., FACR, vice president and director of advanced imaging at RadNet, discusses the latest resea
Guerbet, IBM Watson Health Partner on Artificial Intelligence for Liver Imaging
News | Clinical Decision Support | July 10, 2018
Guerbet announced it has signed an exclusive joint development agreement with IBM Watson Health to develop an...
Imaging agent helps predict success of lung cancer therapy
News | Oncology Diagnostics | March 08, 2018
March 8, 2018 – Doctors contemplating the best therapy for...
OptiStar Elite injector
Feature | Contrast Media Injectors | March 07, 2018 | Grand View Research Inc.
The global contrast media injectors market is expected to reach $1.4 billion by 2025, growing at a compound annual...
TriHealth in Cincinnati

TriHealth in Cincinnati.

Sponsored Content | Case Study | Contrast Media Injectors | March 06, 2018
The continuing search for advantages to improve workflow has radiology departments constantly searching for new...
Guerbet Presents Contrast&Care Injection Management Solution at ECR 2018
News | Contrast Media | February 28, 2018
February 28, 2018 — Guerbet will present its new Contrast&Care application, as well as other...